Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Johnson and Johnson
Colorcon
Harvard Business School
Mallinckrodt

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-1236

See Plans and Pricing

« Back to Dashboard

What is the drug development status for AZD-1236?

AZD-1236 is an investigational drug.

There have been 30 clinical trials for AZD-1236. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Small Cell Lung Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are three US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for AZD-1236
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-1236 clinical trials

Clinical Trial Summary for AZD-1236

Top disease conditions for AZD-1236
Top clinical trial sponsors for AZD-1236

See all AZD-1236 clinical trials

US Patents for AZD-1236

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD-1236   Start Trial Metalloproteinase inhibitors AstraZeneca AB (SE)   Start Trial
AZD-1236   Start Trial Metalloproteinase inhibitors AstraZeneca AB (SE)   Start Trial
AZD-1236   Start Trial Metalloproteinase inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD-1236

Drugname Country Document Number Estimated Expiration Related US Patent
AZD-1236 Argentina 035443 2021-03-15   Start Trial
AZD-1236 Argentina 035444 2021-03-15   Start Trial
AZD-1236 Argentina 035695 2021-03-15   Start Trial
AZD-1236 Austria 333454 2021-03-15   Start Trial
AZD-1236 Austria 484496 2021-03-15   Start Trial
AZD-1236 Austria 493406 2021-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Johnson and Johnson
Express Scripts
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.